Skip to main content
Premium Trial:

Request an Annual Quote

Roche Obtains CE Mark for Three Tests on New Cobas PCR Instrument

NEW YORK – Roche announced on Tuesday that it is launching three new tests on its molecular Cobas 5800 instrument in countries accepting the CE mark.

The RT-PCR tests for BK virus, cytomegalovirus, and Epstein-Barr virus received CE marking for use on the Cobas 5800 system in the last couple of weeks, a Roche spokesperson said via email. The tests are intended for use in transplant patients at risk of infection and can run simultaneously on the Cobas 5800.

Roche's Cobas BKV test received 510(k) clearance from the US Food and Drug Administration for use with its high-throughput Cobas 6800 and 8800 systems in 2020. The CMV test garnered FDA approval for the systems in 2017, and the Epstein-Barr virus test was cleared by the agency in 2020.

The existing test menu on the Cobas 5800 includes assays for hepatitis B, hepatitis C, HIV, and SARS-CoV-2, as well as multiplex tests for SARS-CoV-2 and influenza A/B, chlamydia and gonorrhea, and Trichomonas vaginalis and Mycoplasma genitalium.

The Cobas 5800 instrument, which delivers up to 144 results in an eight-hour shift, received CE marking last November.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.